Treatment with compound Lactobacillus acidophilus followed by a tetracycline- and furazolidone-containing quadruple regimen as a rescue therapy for Helicobacter pylori infection

Liu, Airu; Wang, Yuxin; Song, Ying-Xiao; Du, Yiqi

doi:10.4103/sjg.sjg_589_19

Cited by 13 publications

(8 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…pylori eradication have been reported. 7 Previously, we found that probiotics could alleviate patients' discomfort due to antibiotic therapy 34,35 . In the current study we reported an overall incidence of AEs (mostly dizziness, nausea, loose stool, and chest distress) of 16.2%.…”

Section: Discussionsupporting

confidence: 47%

“…7 Previously, we found that probiotics could alleviate patients' discomfort due to antibiotic therapy. 34,35 In the current study we reported an overall incidence of AEs (mostly dizziness, nausea, loose stool, and chest distress) of 16.2%. These findings are consistent with previous studies, 36,37 possibly because prior probiotic treatment regulates intestinal microflora.…”

Section: Effect Of Adjuvant Probiotic Treatment On Aessupporting

confidence: 49%

See 1 more Smart Citation

Effects of probiotics on gastric microbiota and its precombination with quadruple regimen for Helicobacter pylori eradication

You

Dong

Zhou

et al. 2022

J of Digest Diseases

View full text Add to dashboard Cite

Objectives: This study aimed to assess the efficacy and safety of probiotics for Helicobacter pylori (H. pylori) eradication therapy as well as their effects on gastric microbiota.Methods: Patients who had failed H. pylori eradication therapy for at least twice were prospectively enrolled during March 2019 and March 2021. A 2-week administration of compound Lactobacillus acidophilus probiotic (1 g thrice daily) followed by a 10-day quadruple bismuth-containing H. pylori eradication therapy was administrated. Endoscopy was performed, and gastric biopsy samples were obtained for drug sensitivity testing and 16S rRNA gene sequencing before and after probiotic treatment. Eradication was evaluated by the 13 C-urea breath test at least 4 weeks after treatment completion. Adverse events (AEs) were recorded.Results: Thirty-seven patients were included. Probiotic supplementation had no effects on the diversity, community structure, and composition of gastric microbiota and no inhibition on H. pylori activity. However, it increased some of the beneficial bacteria such as Blautia, Dorea, and Roseburia (P < 0.05). The overall eradication rate was 97.3% (95% confidence interval [CI] 91.8%-100%). AEs, mainly dizziness, nausea, diarrhea, and chest distress, were detected in six individuals, all of which were resolved upon cessation of antibiotic administration. Dyspeptic symptoms were improved after probiotic supplementation and at treatment completion (both P < 0.001).Conclusions: H. pylori-infected individuals might benefit from probiotics followed by a quadruple bismuth-containing eradication therapy. Further studies with large sample sizes are warranted.

show abstract

Section: Discussionsupporting

confidence: 47%

Section: Effect Of Adjuvant Probiotic Treatment On Aessupporting

confidence: 49%

Effects of probiotics on gastric microbiota and its precombination with quadruple regimen for Helicobacter pylori eradication

You

Dong

Zhou

et al. 2022

J of Digest Diseases

View full text Add to dashboard Cite

show abstract

“…Moreover, the patient’s compliance was exceptionally nice, and side effects were mild in both regimens (Dore et al 2019b ). Bismuth-containing quadruple therapy (BCQT) with probiotic supplementation could achieve excellent eradication rates and produce fewer side effects (Zhu et al 2018 , 2017 ), even in patients who experienced failing treatment before (Liu et al 2020 ). A meta-analysis showed that, compared with the control group (only BCQT), the probiotic group (BCQT with probiotic supplementation) had a higher eradication rate with statistical significance ( P = 0.000), and fewer adverse reactions were reported in the probiotic group than in the control group ( P = 0.000) (Si et al 2017 ).…”

Section: Roles Of Probiotics In H Pylori Eradicati...mentioning

confidence: 99%

The impacts of probiotics in eradication therapy of Helicobacter pylori

Bai

Zhu

et al. 2022

Arch Microbiol

View full text Add to dashboard Cite

Helicobacter pylori (H. pylori) is a well-known pathogen that infects approximately half of the world’s population. It is a pathogenic agent with potential health hazards related to diverse diseases, especially digestive diseases, such as chronic gastritis, peptic ulcer, and gastric carcinoma. In clinical, antibiotics are commonly applied in eradication therapy of H. pylori. However, the increase in antibiotic resistance and side effects has induced the failure of eradication therapy. Recent studies have shown that probiotic supplementation has promising application prospects. It can restore the gastrointestinal microbiota balance and prevent dysbacteriosis caused by antibiotics. Furthermore, it has been reported to have direct or indirect inhibitory effects on H. pylori. Probiotics may have a beneficial effect on H. pylori eradication. However, the strain, dosages, duration times, and safety of probiotic supplementation need further study before clinical applications.

show abstract

“…A study from China treated patients with refractory Helicobacter pylori with Lactobacillus for 2 weeks followed by 10-day quadruplex therapy with tetracycline and furazolidone as rescue treatment. The overall eradication rate was 92% in the intention-to-treat (ITT) analysis and 91.8% in the Per-Protocol (PP) analysis, with fewer adverse reactions and a good safety profile ( Liu et al, 2020 ). The Iranian study also found that in patients in whom eradication had failed, quadruple therapy containing Lactobacillus was more effective as a rescue therapy than non-probiotic treatment ( Karbalaei and Keikha, 2021 ).…”

Section: Options For Rescue Treatment: Antibiotic-susceptibility Test...mentioning

confidence: 99%

Treatment of refractory Helicobacter pylori infection: A new challenge for clinicians

He²,

Zhu³

2022

Front. Microbiol.

View full text Add to dashboard Cite

Patients who have failed two or more attempts to eradicate Helicobacter pylori are commonly referred to as refractory. Although the incidence of refractory Helicobacter pylori infection is only 10–20%, with the increasing rate of antibiotic resistance in various regions, the treatment of refractory Helicobacter pylori infection has gradually become a difficult problem faced by clinicians. When choosing a rescue therapy, the physician must consider numerous factors. A longer treatment duration, higher doses of proton pump inhibitors (PPIs), or the use of potassium-competitive acid blocker (P-CAB) may increase the efficacy of triple therapy or bismuth quadruple therapy. Rescue treatment based on bismuth quadruple therapy usually achieves better results. At the same time, treatment based on drug susceptibility tests or genotypic resistance is recommended where available. Of course, appropriate empiric treatment can also be selected according to local drug resistance, a patient’s previous medication history and compliance. It is the best choice if it can improve the success rate of the first treatment and reduce the occurrence of refractory Helicobacter pylori infection. This review aims to summarize the articles related to refractory Helicobacter pylori in recent years and to explore a better remedial treatment plan for clinicians.

show abstract

Treatment with compound Lactobacillus acidophilus followed by a tetracycline- and furazolidone-containing quadruple regimen as a rescue therapy for Helicobacter pylori infection

Cited by 13 publications

References 39 publications

Effects of probiotics on gastric microbiota and its precombination with quadruple regimen for Helicobacter pylori eradication

Effects of probiotics on gastric microbiota and its precombination with quadruple regimen for Helicobacter pylori eradication

The impacts of probiotics in eradication therapy of Helicobacter pylori

Treatment of refractory Helicobacter pylori infection: A new challenge for clinicians

Contact Info

Product

Resources

About